Compare YSWY & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSWY | OBX |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 764.2M | 861.1M |
| IPO Year | 2021 | 2026 |
| Metric | YSWY | OBX |
|---|---|---|
| Price | $24.74 | $14.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $29.63 | ★ $39.00 |
| AVG Volume (30 Days) | 248.9K | ★ 300.4K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.92 | $11.52 |
| 52 Week High | $26.34 | $39.00 |
| Indicator | YSWY | OBX |
|---|---|---|
| Relative Strength Index (RSI) | 65.76 | 47.42 |
| Support Level | $18.92 | $11.84 |
| Resistance Level | $26.34 | $19.97 |
| Average True Range (ATR) | 0.93 | 1.09 |
| MACD | 0.24 | 0.40 |
| Stochastic Oscillator | 87.61 | 56.78 |
Yesway Inc is a U.S.-based convenience store operator that manages retail locations under the Yesway and Allsup's brands. Its stores offer foodservice products, grocery items, and private-label products. The company operates in rural and suburban markets across the Southwest and Midwest regions of the United States. It derives its revenue in the United States by operating convenience stores that offer merchandise, fuel, and other products and services designed to appeal to the convenience needs of the customers.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.